<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00814931</url>
  </required_header>
  <id_info>
    <org_study_id>AG0114</org_study_id>
    <nct_id>NCT00814931</nct_id>
  </id_info>
  <brief_title>Examining the Effects of CXB722 in Neuroendocrine Stress Response in Healthy Males</brief_title>
  <acronym>CXB722-100</acronym>
  <official_title>A Phase 1, Multiple Dose, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Examining the Effects of CXB722 in Mitigating Neuroendocrine Stress Response in Healthy Males</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CeNeRx BioPharma Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute on Aging (NIA)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the effects of CXB722 on neuroendocrine stress&#xD;
      response and subjective reports related to mood and stress during and after experimentally&#xD;
      induced stress among healthy young males.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acute stress produces a cascade of physiological and psychological effects, including&#xD;
      increased cardiovascular function, increases in circulating levels of stress hormones and&#xD;
      neurotransmitter levels, and changes in mood and subjective state. The Trier Social Stress&#xD;
      Test (TSST) is a standardized, well-validated procedure that was developed in order to&#xD;
      provide a controlled method for exposing subjects to a stressor. The TSST consists of a&#xD;
      public speaking and a mental arithmetic test performed in the context of a mock job&#xD;
      interview.&#xD;
&#xD;
      A drug that could safely block or mitigate the stress response would have multiple&#xD;
      applications in medicine, beyond treating anxiety, because stress is associated with many&#xD;
      disease states, including cardiovascular disease. The drug being studied, CXB722, is thought&#xD;
      to show promise in diminishing the physiologic and psychological effects of stress.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma cortisol and salivary cortisol levels</measure>
    <time_frame>Screening and Study Day 8</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma ACTH</measure>
    <time_frame>Screening and Study Day 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma epinephrine and norepinephrine</measure>
    <time_frame>Screening and Study Day 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Profile of Mood States (POMS) Tension-Anxiety</measure>
    <time_frame>Screening and Study Day 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue-Inertia, and Vigor-Activity factor scores</measure>
    <time_frame>Screening and Study Day 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>&quot;State&quot; score on the Spielberger State-Trait Anxiety Scale (SSTAS)</measure>
    <time_frame>Screening and Study Day 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seven Visual Analog Scales (VAS)</measure>
    <time_frame>Screening and Study Day 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HR, and systolic and diastolic BP</measure>
    <time_frame>Screening and Study Day 8</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Stress</condition>
  <condition>Anxiety</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment Group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CXB722</intervention_name>
    <description>900 mg CXB722 oral liquid suspension twice a day for 8 days</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Pivagabine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>matching oral liquid suspension placebo twice a day for 8 days</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male, 18 to 34 years of age, inclusive, at screening&#xD;
&#xD;
          -  Able to read, understand and converse in English&#xD;
&#xD;
          -  Able to read, understand, and provide written, dated informed consent&#xD;
&#xD;
          -  Willing to refrain from the use of any concomitant medications (including over-the&#xD;
             counter (OTC)) and nutritional/herbal supplements and comply with all study&#xD;
             requirements&#xD;
&#xD;
          -  Willing to submit to daily breathalyzer testing each day study medication is&#xD;
             administered over the course of the study&#xD;
&#xD;
          -  In good general health as ascertained by medical history, physical examination (PE)&#xD;
             including measurement of vital signs, clinical laboratory evaluations, and 12-lead&#xD;
             electrocardiogram (ECG)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence on physical examination or laboratory findings of chronic liver or renal&#xD;
             disease or other chronic physical disorders&#xD;
&#xD;
          -  Evidence of cardiovascular disease on 12 lead ECG, vital signs or laboratory findings&#xD;
&#xD;
          -  Significant anxiety as indicated by a score of 47 or higher on the &quot;Trait&quot; score of&#xD;
             Spielberger State-Trait Anxiety Scale&#xD;
&#xD;
          -  Family history (first degree relative) of hypertension or cardiovascular disease prior&#xD;
             to age 40&#xD;
&#xD;
          -  Evidence on physical or laboratory examination of endocrinopathies or immunopathies,&#xD;
             including HIV&#xD;
&#xD;
          -  BMI of 30 or greater, evidence of significant recent weight change or history of&#xD;
             obesity&#xD;
&#xD;
          -  History of any psychiatric disorder, or evidence of such a disorder based on a&#xD;
             psychiatric evaluation which includes the Structured Clinical Interview for DSM-IV-TR&#xD;
             (SCID)&#xD;
&#xD;
          -  History of any physical condition which, in the investigator's opinion, might put the&#xD;
             participant at risk or interfere with the interpretation of study results&#xD;
&#xD;
          -  Use of any prescription or over-the-counter (OTC) medications (including herbal&#xD;
             remedies) within 14 days of study randomization&#xD;
&#xD;
          -  Use of tobacco products or any nicotine-containing products (e.g., gum, patch) within&#xD;
             the past 6 months (prior to screening)&#xD;
&#xD;
          -  Positive screening urine test for nicotine or drugs of abuse: cannabinoids, cocaine,&#xD;
             amphetamines, barbiturates, opiates, benzodiazepines, or alcohol in the blood&#xD;
&#xD;
          -  Unwillingness to agree to avoid strenuous activity over the course of the study&#xD;
&#xD;
          -  Poor likelihood, in the investigator's judgment, of full cooperation during the study&#xD;
             and/or poor compliance is anticipated&#xD;
&#xD;
          -  Previously screened for this trial&#xD;
&#xD;
          -  Consumes more than four cups of coffee daily&#xD;
&#xD;
          -  Deviates from normal nocturnal sleeping patterns&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>34 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlos Santana, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>USF Physicians Group, Associate Professor, Director of Adult Outpatient Services, Department of Psychiatry and Behavioral Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Kirschbaum C, Pirke KM, Hellhammer DH. The 'Trier Social Stress Test'--a tool for investigating psychobiological stress responses in a laboratory setting. Neuropsychobiology. 1993;28(1-2):76-81.</citation>
    <PMID>8255414</PMID>
  </reference>
  <reference>
    <citation>Kirschbaum C, Strasburger CJ, Langkr√§r J. Attenuated cortisol response to psychological stress but not to CRH or ergometry in young habitual smokers. Pharmacol Biochem Behav. 1993 Mar;44(3):527-31.</citation>
    <PMID>8451256</PMID>
  </reference>
  <verification_date>January 2009</verification_date>
  <study_first_submitted>December 23, 2008</study_first_submitted>
  <study_first_submitted_qc>December 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 25, 2008</study_first_posted>
  <last_update_submitted>January 9, 2009</last_update_submitted>
  <last_update_submitted_qc>January 9, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 13, 2009</last_update_posted>
  <responsible_party>
    <name_title>Carlos Santana, MD</name_title>
    <organization>USF Physicians Group</organization>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

